![Tom Wilton](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Tom Wilton
Corporate Officer/Principal bei
LOGICBIO THERAPEUTICS, INC.
Profil
Tom Wilton currently works at LogicBio Therapeutics, Inc., as Chief Business Officer.
Mr. Wilton also formerly worked at Carisma Therapeutics, Inc., as Chief Business Officer from 2019 to 2025.
Mr. Wilton received his graduate degree from Brunel University, graduate degree from the University of Leeds, and undergraduate degree from the University of London.
Aktive Positionen von Tom Wilton
| Unternehmen | Position | Beginn |
|---|---|---|
| LOGICBIO THERAPEUTICS, INC. | Corporate Officer/Principal | - |
Ehemalige bekannte Positionen von Tom Wilton
| Unternehmen | Position | Ende |
|---|---|---|
| CARISMA THERAPEUTICS, INC. | Corporate Officer/Principal | 01.04.2025 |
Ausbildung von Tom Wilton
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
26
Beziehungen ersten Grades
5
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 5 |
|---|---|
Brunel University
 Brunel University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Leeds
 University of Leeds Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of London
 University of London Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
LogicBio Therapeutics, Inc.
 LogicBio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes medicines and therapies for bone metabolism, cardiology, neurology and rare diseases | Health Technology |
Carisma Therapeutics, Inc.
 Carisma Therapeutics, Inc. BiotechnologyHealth Technology Develops novel chimeric antigen receptor macrophage and CAR-monocyte technology treatment of non-muscle invasive bladder cancer | Health Technology |
